

DAVID HOLLAND

Partner

David is a partner in the Life Sciences practice group and has a diverse practice, working with therapeutic proteins, modified nucleic acids and traditional small molecules. He frequently handles platform technology cases, from drafting provisionals to worldwide prosecution, and from divisional strategy to post-grant opposition. In addition, David's familiarity with Supplementary Protection Certificates (SPCs) allows him to provide his clients with comprehensive advice and judicious strategy, drawing upon his experience of patent and regulatory exclusivity.

David's practice focuses on managing interrelated oppositions and appeals at the EPO, often providing strategic advice where his client is opponent in one case and proprietor in the next. He regularly defends patents against multiple opponents in oppositions involving 100+ documents and the very latest case law. David's experience in EPO prosecution, opposition and appeal proceedings has led to significant financial success for his clients. Most recently, his guidance through the initial examination process led to his client, Ionis, successfully defeating nine oppositions to maintain their commanding platform technology portfolio in the antisense space.

David also advises on patent term extensions in Europe (SPCs) for a wide range of products, including Jakavi, Rebif and Evarrest. He works with his clients to optimise their applications, ensuring they have the opportunity to benefit from SPC protection and any available paediatric extension. As part of this work, he assesses both the SPC and patent coverage, and the interplay with the regulatory protection available to his clients (including orphan protection). David is frequently involved in appeals against SPC refusals across Europe, including litigation in Spain and Sweden.

David was awarded a first-class degree in Natural Sciences from the University of Cambridge. He took full advantage of the breadth of this course by studying subjects as diverse as biochemistry, pharmacology and physiology, before focusing on organic and biological chemistry. This combination of experience gives David a particular edge when advising on products at the intersection of these fields, such as therapeutic polymers, antisense oligonucleotides and chemically modified proteins.

Qualifications

- MA (Cambridge)
- MSci (Natural Sciences)
- Chartered Patent Attorney
- European Patent Attorney